Advertisement
COO vs DHR
Which Stock Would AI Choose? The Cooper Companies (COO) vs. Danaher Corporation (DHR) Stock Comparison
Key Takeaways
- The Cooper Companies (COO) operates primarily in contact lenses and women's health products, with recent market activity influenced by upcoming earnings and efficiency initiatives.
- Danaher Corporation (DHR) focuses on life sciences tools, diagnostics, and bioprocessing, showing signs of recovery in equipment orders during recent quarters.
- Relative performance in recent weeks has reflected broader healthcare sector pressures, with both stocks exhibiting volatility tied to macroeconomic factors and sector-specific demand.
- COO maintains a smaller market capitalization and more concentrated exposure to consumer and surgical medical devices compared to DHR's diversified portfolio across multiple healthcare subsectors.
- Growth drivers differ markedly: COO emphasizes product innovation in vision care, while DHR benefits from bioprocessing and diagnostics cycles.
- Market sentiment for both remains neutral to cautious amid ongoing economic uncertainty, with no clear short-term catalysts dominating recent trading.
Introduction
This comparison examines COO and DHR to provide traders and investors with insights into their relative positioning within the healthcare sector. Both companies operate in medical technology and life sciences spaces but serve distinct end markets, making the analysis relevant for those evaluating portfolio diversification, sector rotation strategies, or relative value opportunities. The discussion draws on observable business models, recent performance trends, and market dynamics to highlight trade-offs without favoring either security.
COO Overview and Recent Performance
The Cooper Companies, Inc. develops, manufactures, and markets contact lenses through its CooperVision segment and fertility, women's health, and surgical products via CooperSurgical. In recent weeks, the stock has reflected steady but measured trading activity amid preparations for the upcoming second-quarter 2026 earnings release scheduled for June 4. Earlier fiscal first-quarter results highlighted operational efficiencies and targeted investments in high-return areas. Sentiment has been shaped by broader medical device demand patterns and product ramp-ups in myopia management and fertility offerings, with performance influenced by pricing dynamics in the contact lens market.
DHR Overview and Recent Performance
Danaher Corporation provides biotechnology, life sciences, and diagnostics products through its core platforms. Recent market activity has been supported by first-quarter 2026 results released in April, which showed revenue growth and an increase in the upper end of full-year adjusted earnings guidance. Bioprocessing equipment orders rose notably year-over-year, signaling potential stabilization in that segment after prior inventory adjustments. Performance in recent weeks has been influenced by healthcare sector sentiment, conference presentations, and consistent dividend declarations, with trading reflecting the company's scale in diagnostics and research tools.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of AI trading bots from hundreds available across the platform. These bots trade thousands of different tickers using varied strategies, timeframes, and performance metrics tailored to current market conditions. Only the highest-performing and most suitable options, based on backtested statistics such as win rates, drawdowns, and return ranges, earn placement in the trending section. Users can explore bots with differing risk profiles and ticker focus to align with individual trading styles. Visit the page for detailed performance data and bot specifications.
Head-to-Head Comparison
Business models present clear contrasts: COO concentrates on consumer-facing vision care and procedural medical devices, while DHR spans broader life sciences instrumentation and diagnostics with significant recurring revenue from consumables. Growth drivers for COO center on contact lens innovation and surgical portfolio expansion, whereas DHR draws momentum from bioprocessing recovery and diagnostics demand cycles. Recent momentum shows DHR benefiting from order book improvements, while COO awaits earnings clarity. Risk factors include COO's higher sensitivity to consumer discretionary spending and DHR's exposure to capital equipment cycles. Sector exposure remains healthcare for both, though DHR's larger scale and diversified subsector presence offer different stability characteristics than COO's more focused positioning. Market sentiment for each has tracked healthcare volatility without pronounced divergence in recent periods.
Tickeron AI Verdict
Based on observable factors including trend consistency in order recovery and relative positioning within resilient subsectors, Tickeron’s AI models currently assign a probabilistic edge to DHR over COO in the near term. This assessment reflects DHR's demonstrated bioprocessing stabilization and broader platform diversification, which may provide more consistent signals amid sector fluctuations. Outcomes remain subject to evolving earnings data and macroeconomic variables.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Disclaimers and LimitationsTo compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COO is a Hold and DHR is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
COO’s FA Score shows that 1 FA rating(s) are green whileDHR’s FA Score has 1 green FA rating(s).
- COO’s FA Score: 1 green, 4 red.
- DHR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
COO’s TA Score shows that 5 TA indicator(s) are bullish while DHR’s TA Score has 5 bullish TA indicator(s).
- COO’s TA Score: 5 bullish, 4 bearish.
- DHR’s TA Score: 5 bullish, 5 bearish.
Price Growth
COO (@Pharmaceuticals: Other) experienced а -3.45% price change this week, while DHR (@Medical Specialties) price change was -1.61% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.77%. For the same industry, the average monthly price growth was -0.42%, and the average quarterly price growth was -14.37%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.70%. For the same industry, the average monthly price growth was +2.77%, and the average quarterly price growth was -3.13%.
Reported Earning Dates
COO is expected to report earnings on Sep 02, 2026.
DHR is expected to report earnings on Jul 28, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (-1.77% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (+0.70% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| COO | DHR | COO / DHR | |
| Capitalization | 12.8B | 126B | 10% |
| EBITDA | 1.08B | 7.08B | 15% |
| Gain YTD | -20.181 | -21.995 | 92% |
| P/E Ratio | 55.44 | 34.53 | 161% |
| Revenue | 4.15B | 24.8B | 17% |
| Total Cash | 125M | 5.7B | 2% |
| Total Debt | 2.5B | 18.5B | 14% |
COO | DHR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 11 | 81 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 72 Overvalued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 86 | 80 | |
PRICE GROWTH RATING 1..100 | 59 | 60 | |
P/E GROWTH RATING 1..100 | 14 | 60 | |
SEASONALITY SCORE 1..100 | 46 | 30 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DHR's Valuation (10) in the Medical Specialties industry is somewhat better than the same rating for COO (72). This means that DHR’s stock grew somewhat faster than COO’s over the last 12 months.
DHR's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as COO (100). This means that DHR’s stock grew similarly to COO’s over the last 12 months.
DHR's SMR Rating (80) in the Medical Specialties industry is in the same range as COO (86). This means that DHR’s stock grew similarly to COO’s over the last 12 months.
COO's Price Growth Rating (59) in the Medical Specialties industry is in the same range as DHR (60). This means that COO’s stock grew similarly to DHR’s over the last 12 months.
COO's P/E Growth Rating (14) in the Medical Specialties industry is somewhat better than the same rating for DHR (60). This means that COO’s stock grew somewhat faster than DHR’s over the last 12 months.
| COO | DHR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 60% | 2 days ago 56% |
| Stochastic ODDS (%) | 2 days ago 55% | 2 days ago 56% |
| Momentum ODDS (%) | 2 days ago 62% | 2 days ago 62% |
| MACD ODDS (%) | N/A | 2 days ago 67% |
| TrendWeek ODDS (%) | 2 days ago 60% | 2 days ago 64% |
| TrendMonth ODDS (%) | 2 days ago 49% | 2 days ago 54% |
| Advances ODDS (%) | 19 days ago 57% | 8 days ago 54% |
| Declines ODDS (%) | 8 days ago 60% | 6 days ago 60% |
| BollingerBands ODDS (%) | 2 days ago 65% | 2 days ago 65% |
| Aroon ODDS (%) | 2 days ago 50% | 2 days ago 50% |
Advertisement
COO and
Correlation & Price change
A.I.dvisor indicates that over the last year, COO has been loosely correlated with BDX. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if COO jumps, then BDX could also see price increases.
DHR and
Correlation & Price change
A.I.dvisor indicates that over the last year, DHR has been closely correlated with TMO. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if DHR jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To DHR | 1D Price Change % | ||
|---|---|---|---|---|
| DHR | 100% | +0.58% | ||
| TMO - DHR | 77% Closely correlated | -0.13% | ||
| A - DHR | 73% Closely correlated | -0.45% | ||
| RGEN - DHR | 68% Closely correlated | -4.05% | ||
| RVTY - DHR | 64% Loosely correlated | -0.96% | ||
| BIO - DHR | 64% Loosely correlated | -0.47% | ||
More | ||||